PRODUCT RELEASE: VWF ANTIGEN -- MEDICA - World Forum for Medicine

08/04/2022

Nordic Biomarker AB

PRODUCT RELEASE: VWF ANTIGEN

We are celebrating the official launch of our newest product: vWF Antigen!

vWF is short for “von Willebrand factor”, which is a large protein that plays an important part in the coagulation process. Von Willebrand disease (vWD) is the most common hereditary bleeding disorder, affecting up to 1% of the population. The condition means that the patient has either an insufficient quantity or insufficient quality of vWF, which leads to abnormal bleeding. The diagnosis process is complicated and requires many different steps, where a vWF Antigen assays is one. 

This has been a long journey, and we are terribly proud to finally let the rest of the world meet our newest reagent! It is liquid, ready-to-use and has a long open-vial stability of 10 weeks.

If you have any questions or want to evaluate this or any other reagent, please send an email to sales@nordicbiomarker.com.

Exhibitor Data Sheet